Last updated: April 12, 2026
What is UDENYCA?
UDENYCA (pegfilgrastim-cbqv) is a biosimilar to Neulasta (pegfilgrastim). It is a long-acting granulocyte-colony stimulating factor (G-CSF) used to reduce the incidence of febrile neutropenia in patients receiving chemotherapy.
Market Size and Growth Drivers
Global Market Valuation
- The global G-CSF market exceeded $5 billion in 2022.
- UDENYCA contributes a significant portion, with biosimilars representing approximately 45% of the segment.
Growth Factors
- Expanding use in chemotherapy patients.
- Increasing adoption of biosimilars to lower healthcare costs.
- Patent expiration of originator products prompting biosimilar entry.
Adoption Trends
- Biosimilars accounted for 40% of the neutropenia treatment market in 2022.
- Expected annual growth rate of biosimilar G-CSFs: 8-10% through 2027 (Grand View Research, 2023).
Competitive Landscape
| Product |
Company |
Approval Year |
Market Share (2022) |
Price Advantage |
Key Differentiators |
| Neulasta |
Amgen |
2002 |
60% |
N/A |
Original patent holder |
| UDENYCA |
Coherus Biosciences |
2020 |
20% |
25-30% lower |
Biosimilar, affordability |
| BINAXEO (MYL-1401A) |
Mylan |
2018 |
10% |
30% lower |
Multiple biosimilar options |
| Others |
Several competitors |
Varies |
10% |
Varies |
Regional players |
Amgen's Neulasta remains dominant, but biosimilars like UDENYCA are gaining share, driven by price competition and healthcare policies favoring biosimilar use.
Regulatory and Reimbursement Policies
- UDENYCA gained FDA approval in September 2020.
- Several countries, including EU members, have policies encouraging biosimilar uptake.
- The US Centers for Medicare & Medicaid Services (CMS) implemented policies favoring biosimilar substitution, impacting UDENYCA’s market penetration.
- Reimbursement prices are approximately 20-30% lower than originator in most markets, incentivizing hospitals and payers.
Financial Performance and Trajectory
Revenue Trends (2020–2022)
| Year |
Revenue (USD millions) |
Growth Rate |
Key Factors |
| 2020 |
$60 |
- |
Launch year, initial uptake |
| 2021 |
$150 |
150% |
Steady adoption, expanding markets |
| 2022 |
$270 |
80% |
Increased market penetration |
Revenue Drivers
- Volume growth due to broader biosimilar acceptance.
- Price reductions in line with biosimilar competition.
- Expanding approvals in new regions.
Cost Structure
- Manufacturing costs are approximately 25% lower than originator.
- Marketing and sales expenses focus on education around biosimilar benefits.
- R&D spending minimal post-launch, primarily for lifecycle management.
Profitability Outlook
- Gross margins estimated at 60–65%, slightly below Neulasta due to pricing pressures.
- EBITDA margins projected at 25–30% as volume scales and production efficiencies improve.
- Break-even achieved in the second year post-launch, with profitability expected to increase through 2023–2025.
Challenges and Risks
- Slow adoption due to physician and patient preferences for originator.
- Regulatory delays or restrictions in certain markets.
- Price competitiveness pressured by new biosimilar entries.
- Potential manufacturing or supply chain disruptions affecting margins.
Future Market Outlook
Projections (2023–2027)
- Revenue CAGR of 8–12% across key geographies.
- Biosimilar penetration in the US expected to reach 55%–60% by 2025.
- Growing acceptance in emerging markets, driven by price sensitivity.
- Potential pipeline developments include biosimilars for other G-CSFs and expanded indications.
Strategic Initiatives
- Engaging healthcare providers through education programs.
- Expanding regional approvals.
- Leveraging payer negotiations to secure favorable formulary placements.
- Developing additional biosimilars or combination therapies.
Key Takeaways
- UDENYCA is a leading biosimilar in the G-CSF segment, with a fast-growing market share post-approval.
- Biosimilar entry has driven price competition, pressuring originator revenue.
- Revenues increased sharply from 2020 to 2022, with continued growth forecasted.
- Market adoption hinges on regulatory environments, payer policies, and physician acceptance.
- Cost efficiencies and strategic regional expansion will be critical to achieving sustained profitability.
FAQs
1. What differentiates UDENYCA from its competitors?
UDENYCA offers a biosimilar alternative at approximately 25-30% lower cost than Neulasta, supported by rapid regulatory approvals and targeted regional expansion.
2. How does regulatory policy impact UDENYCA’s market?
Stringent approval processes and approval delays in certain countries can slow uptake, while policies favoring biosimilar substitution boost market penetration.
3. What are the key growth regions for UDENYCA?
The US, European Union, and emerging markets like China and Brazil are primary growth drivers, reflecting expanding acceptance and healthcare reimbursement policies.
4. What risks could hinder UDENYCA’s financial trajectory?
Delayed adoption, market saturation by biosimilar entrants, and supply chain issues could impact revenue growth.
5. How does UDENYCA’s manufacturing impact its financial outlook?
Lower manufacturing costs support higher margins, but capacity constraints or quality issues could increase expenses and reduce profitability.
Sources
- Grand View Research (2023). "Biosimilars Market Size, Share & Trends Analysis."
- FDA (2020). UDENYCA Approval Notice.
- IQVIA (2022). "Global Oncology Biosimilars Report."
- Centers for Medicare & Medicaid Services. (2022). Biosimilar Policies Impacting Market Dynamics.
- Coherus Biosciences. (2020). UDENYCA Launch Transcript.
